This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 163 studies, archived under the term: "Other"

Click here to filter this large number of results.

Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial
Unlabelled: Patients with cognitive impairment (CI) often do not receive secondary fracture prevention. Use of zoledronic acid led to a similar reduction in re-fracture risk but the survival benefit was limited to those without CI.; Introduction: We tested whether the effects of id (Zol) on re-frazoledronic accture and mortality differed in patients presenting with a […]

Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer’s disease
Background: Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are associated with reduced rates of cognitive decline in patients with dementia. CACE-Is may also improve exercise tolerance in functionally impaired older adults with normal cognition, suggesting that CACE-Is may positively influence activities of daily living (ADL) in dementia.; Objective: To compare rates of decline in patients […]

Long-term metformin usage and cognitive function among older adults with diabetes
Evidence strongly supports the important role of insulin resistance in cognitive decline and dementia and suggests that insulin sensitizers may protect against cognitive decline in diabetic and pre-diabetic individuals. Inconclusive results have been reported in clinical trials of rosiglitazone, an insulin sensitizer that also increases cardiovascular mortality risks. No study has yet reported a protective […]

The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]

Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients
Dopamine is a neurotransmitter involved in several brain functions ranging from emotions control, movement organization to memory formation. It is also involved in the regulation of mechanisms of synaptic plasticity. However, its role in Alzheimer’s disease (AD) pathogenesis is still puzzling. Several recent line of research instead indicates a clear role for dopamine in both […]

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]

Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease
Background: Evidence supports a role of α4β2 receptors in Alzheimer’s disease (AD).; Methods: This Korean, multicenter, double-blind, two-period (6 weeks each), crossover study randomized participants to the order in which they received varenicline (1 mg twice daily) and placebo. Assessments included AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 75, Neuropsychiatric Inventory (NPI), adverse events (AEs) and Columbia-Suicide […]

Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial
Background: Observational studies report a relationship between anticholinergic drug scale (ADS) score and cognitive function. This study investigated whether a reduced ADS score improved cognitive function in a frail elderly population.; Methods: This randomized, controlled, single-blinded trial, recruited long-term residents with an ADS score of greater than or equal to 3 from 22 nursing homes […]

Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study
Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer’s disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the […]

Adverse drug reactions in elderly subjects hospitalized in a specialized dementia management unit
Introduction: Drug prescriptions represent an actionable item in the prevention of adverse drug reactions (ADRs). The aims of this study were to identify risk factors for the occurrence of ADRs, and to describe symptoms and drug interactions. Methods: This was a longitudinal study over a period of 19 months in an acute geriatric ward specializing […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us